Page last updated: 2024-08-24

valsartan and Left Ventricular Dysfunction

valsartan has been researched along with Left Ventricular Dysfunction in 119 studies

Research

Studies (119)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.84)	18.2507
2000's	45 (37.82)	29.6817
2010's	33 (27.73)	24.3611
2020's	40 (33.61)	2.80

Authors

Authors	Studies
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A	1
Fu, G; Lu, J; Shen, C; Xiong, C; Yang, Y	1
Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y	1
Abumayyaleh, M; Akin, I; Aweimer, A; Behnes, M; Demmer, J; El-Battrawy, I; Krack, C; Lang, S; Mügge, A; Pilsinger, C	1
Cheang, I; Dai, C; Li, X; Liao, S; Lu, Q; Lu, X; Shi, S; Su, X; Wang, J; Xu, D; Yuan, F; Yuan, J; Zhang, M; Zhao, Y; Zhou, J; Zhu, X	1
Addison, D; Breathett, K; Brewer, LC; Essien, UR; Johnson, AE; Magnani, JW; Mazimba, S; Mohammed, SF; Swabe, GM	1
Campanile, A; Carrizzo, A; Ciccarelli, M; Citro, R; Correale, M; Cuomo, A; Dattilo, G; Di Pietro, P; Galasso, G; Giallauria, F; Masarone, D; Mazzeo, P; Mercurio, V; Pacileo, G; Radano, I; Ravera, A; Silverio, A; Tocchetti, CG; Vecchione, C; Visco, V	1
Jatić, Z; Kulić, M; Naser, N	1
Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM	1
Gao, M; Gong, L; Wang, X; Wang, Z; Wei, Z; Zhang, M; Zhang, Q; Zhang, Z	1
Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, HT; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY	1
Basu, T; Birati, E; Brady, P; Chopra, V; Hummel, SL; Kamdar, N; Nallamothu, BK; Shore, S	1
Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Udell, JA	1
Abushanab, D; Al-Badriyeh, D; Alyafei, SA; Arabi, AR; Kaddoura, R	1
Cho, GY; Hwang, IC; Kim, HK; Kim, SH; Kim, YJ; Lee, HJ; Lee, SP; Moon, MG; Park, JB; Yoon, YE	1
Beckendorf, J; Estler, B; Frankenstein, L; Frey, N; Fröhlich, H; Mäck, M; Schlegel, P; Täger, T	1
Abuyousef, S; Ahmed, E; Alyafei, S; Hamou, F; Kasem, M; Mahfouz, A; Orabi, B; Rahhal, A; Shoukry, AE	1
Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH	2
Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, CG; Ducrocq, G; Granger, C; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Leng, DSK; Lewis, EF; Maggioni, A; Mann, DL; McMurray, JJV; Mehran, R; Petrie, M; Pfeffer, MA; Rouleau, JL; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y	1
Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C	1
Benini, A; Bingel, A; Edelmann, F; Messroghli, D; Neumann, K; Pieske, B; Schönrath, F	1
Bonnet, D; Burch, M; Garito, T; Kantor, PF; Kocun, M; Shaddy, R; Solar-Yohay, S; Zhang, S	1
Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA	1
Appelbaum, JS; Huetteman, AT; Reyes, EA; Zhang, H	1
Pandya, A; Spahillari, A; Yan, BW	1
Alarco, W; Figueroa, Y; Gómez-Mesa, JE; Magaña, A; Pow-Chon, F; Quesada, D; Ramos, CE; Rodríguez-García, D; Rossel, V; Saldarriaga, C; Speranza, M; Ventura-Umanzor, JR	1
De Vecchis, R; Di Maio, M; Paccone, A	2
Chang, HY; Chen, KC; Chong, E; Feng, AN; Fong, MC; Fu, HN; Huang, KC; Yin, WH	1
Gholkar, G; Kado, H; Khan, Z; Tolia, S; Zughaib, M	2
Auria, F; Bonadies, D; Carrizzo, A; Ciccarelli, M; Citro, R; De Angelis, E; Galasso, G; Gigantino, A; Iaccarino, G; Loria, F; Polito, MV; Rispoli, A; Silverio, A; Vecchione, C; Vitulano, G	1
Fu, X; Wang, H	1
Crea, F; Lamendola, P; Lanza, GA; Leone, D; Lombardo, A; Melita, V; Mercuri, EM; Palermo, C; Pane, M; Pennestrì, F; Villano, A	1
Barrios, V; Clark, AL; Damy, T; Drożdż, J; Ferber, PC; Fonseca, C; Hussain, RI; Kalus, S; Koch, C; Lund, LH; Maggioni, AP; Zeymer, U	1
Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K	1
Beavers, JC; Orvin, NJ; Russell, SD	1
Aroor, AR; Chandrasekar, B; Das, N; DeMarco, VG; Habibi, J; Jia, G; Lastra, G; Lopez-Alvarenga, JC; Mummidi, S	1
Brooksbank, KJM; Campbell, RT; Docherty, KF; Dreisbach, JG; Forsyth, P; Godeseth, RL; Hopkins, T; Jackson, AM; Jhund, PS; Lee, MMY; McConnachie, A; McMurray, JJV; Petrie, MC; Roditi, G; Squire, IB; Stanley, B; Welsh, P	1
Briasoulis, A; Kuno, T; Ueyama, H	1
Alhan, A; Altay, H; Altın, C; Ataş, AE; Baş, MM; Çakmak, HA; Demirkan, B; Dereli, S; Durakoğlugil, ME; Ekici, B; Fahri Erkan, A; Karavelioğlu, Y; Kılıçaslan, B; Kılıçaslan, F; Kıvrak, T; Küçük, M; Olgun, FE; Özkan, H; Şabanoğlu, C; Tengiz, İ; Yaman, M; Yenerçağ, M; Yiğit, Z; Zoghi, M	1
Camerotto, A; Cuppini, S; Mazza, A; Minuz, P; Rigatelli, G; Rubello, D; Schiavon, L; Torin, G; Townsend, DM	1
Brunetti, ND; Correale, M; Di Biase, M; Diella, C; Ferraretti, A; Iacoviello, M; Mallardi, A; Mazzeo, P; Merolla, G; Romano, V; Tricarico, L	1
Bonnet, D; Burch, M; Bush, C; Canter, C; Chen, F; Halnon, N; Kantor, P; Kochilas, L; Rossano, J; Shaddy, R; Zhao, Z	1
Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Migaj, J; Nessler, J; Pawlak, A; Straburzyńska-Migaj, E	1
Bae, WH; Hong, TJ; Hur, SH; Hwang, JY; Jeong, B; Kim, BS; Kim, KS; Kim, YD; Lee, SG; Lee, SH; Oh, JH; Park, JS; Park, K; Park, TH; Yang, TH	1
Dunlay, SM; Sangaralingham, LR; Sangaralingham, SJ; Shah, ND; Yao, X	1
Ariano, C; De Vecchis, R; Di Biase, G; Noutsias, M	1
Akagi, S; Ito, H; Kondo, M; Miura, D; Miyoshi, T; Nakamura, K; Ohno, Y; Saito, Y; Yoshida, M	1
Chiang, LM; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Zile, MR	1
Antol, DD; Casebeer, AW; DeClue, RW; Russo, PA; Stemkowski, S	1
Krittayaphong, R; Permsuwan, U	1
Adda, J; Agullo, A; Akodad, M; Batistella, P; Huet, F; Kalmanovitch, E; Roubille, C; Roubille, F	1
Cole, R; Jensen, BC; Pal, J; Sauer, AJ; Sharma, N; Vader, J; Yehya, A	1
Hong, GR; Kang, DH; Kim, JJ; Kim, MS; Lee, S; Park, SJ; Park, SW; Shin, SH; Song, JM; Yun, SC	1
Hong, SH; Kim, H; Kim, S; Lee, EK; Park, SK	1
Alexanian, C; Cannon, CP; Doros, G; Ibrahim, NE; Januzzi, JL; Ponirakis, A; Russo, P; Song, Y	1
Califf, R; Claggett, B; Køber, L; Lam, CS; Lewis, E; Liu, J; McEntegart, M; McMurray, JJ; Pfeffer, M; Rouleau, J; Skali, H; Solomon, S; Velazquez, E	1
Cheng, W; Hu, H; Li, X; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J	1
Bělohlávek, J	1
Chaggar, PS; Orsborne, C; Shaw, SM; Williams, SG	1
Sabbah, HN	1
Imaizumi, T; Kai, H; Kuwahara, F; Mizoguchi, M; Mizuta, Y; Nakaura, H; Osada, K; Tahara, N	1
Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP	1
Iwasaka, T; Kawamura, A; Masue, Y; Sugiura, T; Yokoe, H; Yuasa, F	1
Geshi, E; Katagiri, T; Mochizuki, S; Nakano, H; Nanjyo, S; Sato, N; Shibata, T; Suzuki, H; Takano, T; Tanaka, K; Yagi, H; Yamazaki, J	1
Miura, T; Yuda, S	1
Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD	1
Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M	1
Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A	1
Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ	1
Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E	1
Adams, F; Birkenfeld, AL; Engeli, S; Jordan, J; Schroeder, C	1
Bains, J; Smith, WB	1
Baek, H; Cho, YR; Choi, SY; Hong, TJ; Hur, SH; Hwang, JY; Kim, KS; Kim, YD; Lee, SG; Park, JS; Park, K; Park, TH; Yang, TH	1
Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A	1
Altieri, PI; Cangiano, JL; Crespo, MJ; Escobales, N	1
Chen, J; Li, C; Xu, W; Zhou, X	1
Kubota, T; Takeshita, A	1
Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T	1
Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD	1
Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S	1
Deswal, A; Mann, DL	1
Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S	1
McAnulty, JH	1
Liebson, PR	1
Hasenfuss, G	1
Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ	1
Nguyen, A; Sharma, S	1
Jugdutt, BI; Menon, V; Sawicki, G	1
Croom, KF; Keating, GM	1
van Veldhuisen, DJ; Voors, AA	1
Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW	1
Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP	1
Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F	1
Drexler, H; Landmesser, U	1
Anavekar, N; McMurray, J; Pfeffer, M; Skali, H; Solomon, SD; Velazquez, E; Yerra, L; Zelenkofske, S	1
Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S	1
Burghină, D; Cozma, D; Dan, R; Drăgulescu, SI; Petrescu, L; Riviş, AI; Suşan, M; Suşan, RM	1
Califf, RM; Diaz, R; Kober, L; Maggioni, AP; Mareev, V; McMurray, JJ; Murin, J; Reed, SD; Schulman, KA; Van de Werf, F; Velazquez, EJ; White, HD	1
Liu, PP; Maggioni, A; Velazquez, EJ	1
Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ	1
Jugdutt, BI	1
Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD	1
Ott, P	1
Jugdutt, BI; Sawicki, G	1
Bissessor, N; White, H	1
Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S	1
Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H	1
Havranek, EP	1
Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD	1
Goldstein, S; Levine, TB; Mishima, T; Sabbah, HN; Sharov, VG; Shimoyama, H; Tanimura, M	1
Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG	1
Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM	1
Piérard, L	1

Reviews

18 review(s) available for valsartan and Left Ventricular Dysfunction

Article	Year
A narrative review on sacubitril/valsartan and ventricular arrhythmias. Medicine, 2022, Jul-08, Volume: 101, Issue:27 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. JAMA cardiology, 2022, 10-01, Volume: 7, Issue:10 Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis. Current problems in cardiology, 2023, Volume: 48, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2023
Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis. Journal of cardiovascular pharmacology, 2023, 06-01, Volume: 81, Issue:6 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2023
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction. The American journal of cardiology, 2021, 08-15, Volume: 153 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left	2021
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2019
Practical guidance on the use of sacubitril/valsartan for heart failure. Heart failure reviews, 2019, Volume: 24, Issue:2 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Cost of Illness; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2019
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical therapeutics, 2019, Volume: 41, Issue:6 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Health Care Costs; Heart Failure; Humans; Models, Statistical; Republic of Korea; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2019
The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgraduate medical journal, 2017, Volume: 93, Issue:1095 Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2017
Silent disease progression in clinically stable heart failure. European journal of heart failure, 2017, Volume: 19, Issue:4 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2017
Valsartan plus hydrochlorothiazide: a review of its use since its introduction. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Costs; Drug Synergism; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Renal Insufficiency; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2011
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
[Angiotensin receptor blockers in chronic heart failure]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2003
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
[Use of the antihypertensive agent Diovan after acute myocardial infarction]. Revue medicale suisse, 2005, Jun-29, Volume: 1, Issue:26 Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Chronic heart failure: an overview of conventional treatment versus novel approaches. Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2005
Valsartan in the treatment of heart attack survivors. Vascular health and risk management, 2006, Volume: 2, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2006
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2007

Trials

32 trial(s) available for valsartan and Left Ventricular Dysfunction

Article	Year
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. The New England journal of medicine, 2021, 11-11, Volume: 385, Issue:20 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left	2021
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European journal of heart failure, 2022, Volume: 24, Issue:9 Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation, 2022, 12-06, Volume: 146, Issue:23 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Prospective Studies; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial. Circulation. Heart failure, 2023, Volume: 16, Issue:3 Topics: Adolescent; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2023
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. BMC cardiovascular disorders, 2023, 03-13, Volume: 23, Issue:1 Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2023
Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coronary artery disease, 2021, Aug-01, Volume: 32, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Echocardiography; Enalapril; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2021
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Circulation journal : official journal of the Japanese Circulation Society, 2021, 04-23, Volume: 85, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Japan; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2021
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). American heart journal, 2017, Volume: 193 Topics: Adolescent; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Infant, Newborn; Male; Myocardial Ischemia; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2017
The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling. ESC heart failure, 2018, Volume: 5, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Single-Blind Method; ST Elevation Myocardial Infarction; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2018
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation, 2019, 03-12, Volume: 139, Issue:11 Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Republic of Korea; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2019
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European journal of heart failure, 2015, Volume: 17, Issue:3 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk; Risk Factors; Sex Factors; Valsartan; Ventricular Dysfunction, Left	2015
[Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure]. Casopis lekaru ceskych, 2015, Volume: 154, Issue:6 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Chronic Disease; Czech Republic; Drug Combinations; Female; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Survival Rate; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2015
Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment. Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:10 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Echocardiography; Female; Fibrosis; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardium; Prospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2008
Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction. Journal of cardiology, 2009, Volume: 53, Issue:2 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteries; Baroreflex; Drug Synergism; Enalapril; Female; Heart; Hemodynamics; Humans; Lung; Male; Middle Aged; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2009
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European heart journal, 2009, Volume: 30, Issue:18 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European heart journal, 2010, Volume: 31, Issue:2 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American heart journal, 2010, Volume: 160, Issue:1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European journal of heart failure, 2011, Volume: 13, Issue:2 Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2011
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. Trials, 2011, Nov-22, Volume: 12 Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Clinical Protocols; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Sample Size; Single-Blind Method; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2011
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2012, Volume: 25, Issue:5 Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2012
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:6 Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
[AT(1) blocker for post-infarct therapy. VALIANT Study]. Der Internist, 2004, Volume: 45, Issue:8 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis; Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Heart attack patients with complications. Treat with valsartan, captopril, or both? Canadian family physician Medecin de famille canadien, 2004, Volume: 50 Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation, 2005, Jun-28, Volume: 111, Issue:25 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American heart journal, 2005, Volume: 150, Issue:2 Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct Circulation, 2005, Nov-29, Volume: 112, Issue:22 Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2005
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. European journal of heart failure, 2006, Volume: 8, Issue:6 Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2005, Volume: 43, Issue:3-4 Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2005
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart rhythm, 2007, Volume: 4, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2007
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7 Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008

Other Studies

69 other study(ies) available for valsartan and Left Ventricular Dysfunction

Article	Year
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:3 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study. Journal of cardiovascular pharmacology, 2022, 02-01, Volume: 79, Issue:2 Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left	2022
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Journal of cardiovascular translational research, 2022, Volume: 15, Issue:5 Topics: Angiotensin Receptor Antagonists; China; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients. Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:7 Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left	2022
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC heart failure, 2022, Volume: 9, Issue:5 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting. Medical archives (Sarajevo, Bosnia and Herzegovina), 2022, Volume: 76, Issue:2 Topics: Aged; Aminobutyrates; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2022
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy. ESC heart failure, 2022, Volume: 9, Issue:6 Topics: Arrhythmias, Cardiac; Bundle-Branch Block; Cardiac Resynchronization Therapy; Electrocardiography; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2022
Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure. Journal of the American Heart Association, 2022, 09-06, Volume: 11, Issue:17 Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Health Expenditures; Heart Failure; Humans; Medicare; Retrospective Studies; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left	2022
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction. Current problems in cardiology, 2022, Volume: 47, Issue:12 Topics: Cost-Benefit Analysis; Defibrillators, Implantable; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan. JACC. Cardiovascular imaging, 2022, Volume: 15, Issue:9 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Neprilysin; Predictive Value of Tests; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2022
Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:6 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Outpatients; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2022, 10-18, Volume: 80, Issue:16 Topics: Aminobutyrates; Atrial Natriuretic Factor; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Guanosine Monophosphate; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Troponin T; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2022
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry. ESC heart failure, 2023, Volume: 10, Issue:2 Topics: Aged; Atrial Fibrillation; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2023
Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Open heart, 2022, Volume: 9, Issue:2 Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. JACC. Heart failure, 2023, Volume: 11, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2023
Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States. Circulation. Cardiovascular quality and outcomes, 2023, Volume: 16, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left	2023
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC). Archivos de cardiologia de Mexico, 2023, Volume: 93, Issue:Supl Topics: Angiotensin Receptor Antagonists; Cardiology; Consensus; Heart Failure; Humans; Hypertension; Quality of Life; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left	2023
In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blocke Journal of cardiovascular medicine (Hagerstown, Md.), 2019, Volume: 20, Issue:12 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2019
Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Journal of cardiology, 2020, Volume: 75, Issue:3 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Recovery of Function; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2020
Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. Minerva cardioangiologica, 2019, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Retrospective Studies; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2019
Reply to the letter to the editor: Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. International journal of cardiology, 2019, 12-15, Volume: 297 Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Humans; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2019
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction. Scientific reports, 2020, 04-20, Volume: 10, Issue:1 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arterial Pressure; Biphenyl Compounds; Cardiotonic Agents; Case-Control Studies; Diuretics; Drug Combinations; Echocardiography; Female; Furosemide; Heart; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Patient Readmission; Regression Analysis; Retrospective Studies; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2020
Duchenne muscular dystrophy: preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17 Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Humans; Maximum Tolerated Dose; Muscular Dystrophy, Duchenne; Valsartan; Ventricular Dysfunction, Left; Young Adult	2020
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European heart journal. Quality of care & clinical outcomes, 2022, 06-06, Volume: 8, Issue:4 Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. Journal of pharmacy practice, 2022, Volume: 35, Issue:6 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2022
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness. Cardiovascular diabetology, 2021, 04-21, Volume: 20, Issue:1 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cytokines; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Drug Combinations; Male; Myocardium; Neprilysin; Obesity; Protease Inhibitors; Rats, Zucker; Valsartan; Vascular Stiffness; Ventricular Dysfunction, Left; Ventricular Function, Left	2021
Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 07-20, Volume: 144, Issue:3 Topics: Aged; Aminobutyrates; Asymptomatic Diseases; Biomarkers; Biphenyl Compounds; Disease Susceptibility; Drug Combinations; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Neprilysin; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2021
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR). Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:5 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Furosemide; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Retrospective Studies; Stroke Volume; Turkey; Valsartan; Ventricular Dysfunction, Left	2021
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 130 Topics: Aged; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Clinical Studies as Topic; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Patient Readmission; Prognosis; Severity of Illness Index; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2020
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. Acta cardiologica, 2022, Volume: 77, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2022
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kardiologia polska, 2018, Volume: 76, Issue:2 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Patient Safety; Peptide Fragments; Poland; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2018
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. Circulation. Heart failure, 2018, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Young Adult	2018
In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : A retrospective cohort study. Herz, 2019, Volume: 44, Issue:7 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2019
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. Cardiology journal, 2019, Volume: 26, Issue:5 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Fibrosis; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Isoproterenol; Myocardium; Neprilysin; Protease Inhibitors; Rats, Wistar; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2019
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Circulation. Heart failure, 2018, Volume: 11, Issue:5 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2018
An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction. Advances in therapy, 2018, Volume: 35, Issue:6 Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan; Ventricular Dysfunction, Left	2018
Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:5 Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Needs Assessment; Outcome and Process Assessment, Health Care; Quality-Adjusted Life Years; Stroke Volume; Survival Analysis; Tetrazoles; Thailand; Valsartan; Ventricular Dysfunction, Left	2018
Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. International journal of cardiology, 2018, Nov-15, Volume: 271 Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Hemodynamics; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2018
Alteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC heart failure, 2019, Volume: 6, Issue:5 Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Registries; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left	2019
Valsartan ameliorates KIR2.1 in rats with myocardial infarction via the NF-κB-miR-16 pathway. Gene, 2016, Sep-30, Volume: 590, Issue:2 Topics: Animals; Base Sequence; Cell Line; Disease Models, Animal; Hemodynamics; Male; MicroRNAs; Models, Biological; Myocardial Infarction; NF-kappa B; Potassium Channels, Inwardly Rectifying; Rats, Wistar; Reproducibility of Results; Signal Transduction; Up-Regulation; Valsartan; Ventricular Dysfunction, Left	2016
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Experimental physiology, 2009, Volume: 94, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2009
Are treatment effects of ACEI and ARB in post-MI patients homogeneous? Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	2009
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording	2010
Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:2 Topics: Adipocytes; Adrenergic beta-Agonists; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Isoproterenol; Lipolysis; Male; Middle Aged; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan; Ventricular Dysfunction, Left	2011
Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters. Journal of cardiovascular pharmacology, 2012, Volume: 59, Issue:6 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fumarates; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2012
Protective effects of valsartan against cigarette smoke-induced left ventricular systolic dysfunction in rats. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Animals; Cardiotonic Agents; Inflammation Mediators; Male; Oxidative Stress; Random Allocation; Rats; Rats, Wistar; Smoking; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2013
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European journal of heart failure, 2003, Volume: 5, Issue:4 Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Valsartan an alternative to ACE inhibitor in high-risk MI. Geriatrics, 2004, Volume: 59, Issue:1 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent]. MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2003
Valsartan, captopril, or both in myocardial infarction. The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
VALIANT and EUROPA. Preventive cardiology, 2004,Winter, Volume: 7, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 2004, Sep-21, Volume: 110, Issue:12 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. Journal of cardiac failure, 2004, Volume: 10, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Densitometry; Disease Models, Animal; Dogs; Electrocardiography; Electrophoresis, Gel, Two-Dimensional; Heart Rate; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardial Reperfusion; Random Allocation; Tetrazoles; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. International journal of cardiology, 2004, Volume: 97, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Humans; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2004
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart rhythm, 2006, Volume: 3, Issue:3 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cohort Studies; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American heart journal, 2006, Volume: 152, Issue:3 Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Internationality; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Use of valsartan in post-myocardial infarction and heart failure patients. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2006, Volume: 7 Suppl 1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2006, Volume: 19, Issue:12 Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2006
Left bundle branch block is not good for your heart. Heart rhythm, 2007, Volume: 4, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left	2007
Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics, 2007, Volume: 7, Issue:12 Topics: Amino Acids; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Dogs; Mitochondrial Proton-Translocating ATPases; Myocardial Infarction; Myocardial Reperfusion Injury; Necrosis; Phosphorylation; Protein Processing, Post-Translational; Protein Subunits; Proteomics; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:1 Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2008
From black and white to shades of gray: race and renin-angiotensin system blockade. Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People	2008
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People	2008
Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure. The American journal of physiology, 1999, Volume: 276, Issue:4 Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Output, Low; Disease Progression; Dogs; Dose-Response Relationship, Drug; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling	1999
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance. Circulation, 2000, Sep-19, Volume: 102, Issue:12 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left	2000
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). Journal of molecular and cellular cardiology, 2001, Volume: 33, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left	2001
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study]. Revue medicale de Liege, 2002, Volume: 57, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left	2002